Recombinant CD274 (Atezolizumab Biosimilar) 抗体
This anti-CD274 (Atezolizumab Biosimilar) antibody is a Humanized 单克隆 antibody detecting CD274 (Atezolizumab Biosimilar) in FACS 和 in vivo. Suitable for 人.
Quick Overview for Recombinant CD274 (Atezolizumab Biosimilar) 抗体 (ABIN7795089)
抗原
CD274 (Atezolizumab Biosimilar)
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
标记
This CD274 (Atezolizumab Biosimilar) antibody is un-conjugated
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Atezolizumab Biosimilar, Endotoxin 0.05 EU/mg
-
产品特性
- What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab. Atezolizumab lacks the N-glycosylation site in its Fc region by changing an aspartic acid into alanine at amino acid position 298 (amino acid position 297 according to EU nomenclature, N297A) in the heavy chain leading to minimized binding to FcγRs. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- Less than 0.5 EU/mg of protein as determined by LAL method
-
免疫原
- Human PD-L1
-
-
anti-CD274 (Atezolizumab Biosimilar) antibody
Research Grade 适用: 人 FACS, ELISA 宿主: Humanized Monoclonal unconjugated Recombinant Antibody
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- CD274 (Atezolizumab Biosimilar)
-
别名
- Atezolizumab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
